非诺贝特治疗高甘油三酯症和高尿酸症的疗效

Clinical Efficacy of Fenofibrate on Treatment of Hypertriglyceridemia and Hyperuricemia

目的:探讨非诺贝特片治疗高血压病合并高甘油三酯血症和高尿酸血症的疗效。方法:原发性高血压病1～2级伴甘油三酯≥2.3mmol·L^(-1)患者151例,其中合并高尿酸血症83例,依高血压病合并高甘油三酯血症病例随机分组。对照组维生素B_1片10mg,po,tid;治疗组非诺贝特片100mg,po,tid,均连续服药3个月。服药前及服药期满时各取静脉血检查甘油三酯及尿酸。结果:对照组中,甘油三酯在服药后比服药前下降,差异有统计学意义(P<0.05);尿酸服药后比服药前有明显下降,差异有统计学意义(P<0.05)。治疗组中,甘油三酯和尿酸在服药后比服药前均有明显下降,P<0.001。观察组与治疗组服药后比较,后者的TG及UA降低程度较前者更明显P<0.01。结论:非诺贝特片治疗高血压痛合并高甘油三酯血症及高尿酸血症,具有治疗周期短、疗效好的特点。

Objective： To explore the effecacy of fenofibrate on treat of patients with hypertriglyceridemia and hyperuricemia. Method： One hundred and fifty-one cases of essential hypertension with hypertriglyceridemia were chosed, in which 83 patients suffered from hyperuricemia. According to essential hypertension with hypertriglyceridemia patients were divided into 2 groups radomly. In the control group, three meals a day after oral administration of vitamin B1 10mg tid, in the treatment group, oral administration of feno- fibrate 100mg,tid. When treatment of each group was completed, blood samples of triglyeeride and uric acid were tested. Result： TG of the controU group after treatment was decreased slightly than before treatment, it had statistical difference（ P 〈 0.05 ）. UA of the con- trol group was decreased after treatment than before treatment, there were two very significant statistical difference （P 〈 0.001 ）. In thetreatment group, TG and UA after treatment than before treatment were decreased significantly, both statistically significant difference （P 〈0.001 ）. Observer group and treatment group：the latter＇s UA and TG lower than the former was more obvious, between the two groups have a very significant statistical difference （P 〈 0.001 ）. Conclusion： To use fenofibrate treatment of hypertension in patients with hypertriglyceridemia and hyperurieemia, it is found to have the characteristics of a short period of treatment, and a good curative effect.